Ingenol mebutate signals via PKC/MEK/ERK in keratinocytes and induces interleukin decoy receptors IL1R2 and IL13RA2

Molecular Cancer Therapeutics

Volumn 14, Issue 9, 2015, Pages 2132-2142

  Freiberger, Sandra N ^a   Cheng, Phil F ^a   Iotzova Weiss, Guergana ^a   Neu, Johannes ^a   Liu, Qinxiu ^a   Dziunycz, Piotr ^a   Zibert, John R ^b   Dummer, Reinhard ^a   Skak, Kresten ^b   Levesque, Mitchell P ^a   Hofbauer, Günther F L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LEO PHARMA A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INGENOL MEBUTATE; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 13 RECEPTOR ALPHA2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE C DELTA; 3-INGENYL ANGELATE; DITERPENE; PROTEIN KINASE C;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; EXPLANT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; MELANOMA CELL; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN; SQUAMOUS CELL CARCINOMA; UPREGULATION; CELL LINE; CELL SURVIVAL; CLUSTER ANALYSIS; DRUG EFFECTS; GENE EXPRESSION PROFILING; METABOLISM; PHOSPHORYLATION;

CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CLUSTER ANALYSIS; DITERPENES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; KERATINOCYTES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PROTEIN KINASE C; RECEPTORS, INTERLEUKIN-1 TYPE II; SIGNAL TRANSDUCTION;

EID: 84942133860     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0023-T     Document Type: Article

References (41)

1. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006;155:9-22.
2. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000;42:23-4.
3. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 1991;88:10124-8.
4. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91.
5. Hofbauer GF, Attard NR, Harwood CA, McGregor JM, Dziunycz P, Iotzova-Weiss G, et al. Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine. Am J Transplant 2012;12:218-25.
6. Wu X, Nguyen BC, Dziunycz P, Chang S, Brooks Y, Lefort K, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010;465:368-72.
7. Dziunycz PJ, Lefort K, Wu X, Freiberger SN, Neu J, Djerbi N, et al. The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A. J Invest Dermatol 2014;134:1998-2004.
8. Hollestein LM, de Vries E, Nijsten T. Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989-2008. Eur J Cancer 2012;48:2046-53.
9. Lazareth V. Management of non-melanoma skin cancer. Semin Oncol Nurs 2013;29:182-94.
10. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012;366:1010-9.
11. Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol 2009;50:16-22.
12. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol 2010;51:99-105.
13. Ogbourne SM, Suhrbier A, Jones B, Cozzi SJ, Boyle GM, Morris M, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004;64:2833-9.
14. Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006;177:8123-32.
15. Ghoul A, Serova M, Astorgues-Xerri L, Bieche I, Bousquet G, Varna M, et al. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res 2009;69:4260-9.
16. Cozzi SJ, Parsons PG, Ogbourne SM, Pedley J, Boyle GM. Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res 2006;66:10083-91.
17. Olsnes AM, Ersvaer E, Ryningen A, Paulsen K, Hampson P, Lord JM, et al. The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br J Haematol 2009;145:761-74.
18. Stahlhut M, Bertelsen M, Hoyer-Hansen M, Svendsen N, Eriksson AH, Lord JM, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. J Drugs Dermatol 2012;11:1181-92.
19. Rheinwald JG, Beckett MA. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res 1981;41:1657-63.
20. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
21. Long X, Tharp DL, Georger MA, Slivano OJ, Lee MY, Wamhoff BR, et al. The smooth muscle cell-restricted KCNMB1 ion channel subunit is a direct transcriptional target of serum response factor and myocardin. J Biol Chem 2009;284:33671-82.
22. Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blumberg PM. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 2004;64:3243-55.
23. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006;12:99-106.
24. Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK. In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 2001;194:1743-54.
25. Lee CH, Chang JS, Syu SH, Wong TS, Chan JY, Tang YC, et al. IL-1beta promotes malignant transformation and tumor aggressiveness in oral cancer. J Cell Physiol 2015;230:875-84.
26. Yoshimoto T, Yamaai T, Mizukawa N, Sawaki K, Nakano M, Yamachika E, et al. Different expression patterns of beta-defensins in human squamous cell carcinomas. Anticancer Res 2003;23:4629-33.
27. Steinberg SF. Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem J 2004;384:449-59.
28. Liu Y, Belkina NV, Graham C, Shaw S. Independence of protein kinase C-delta activity from activation loop phosphorylation: structural basis and altered functions in cells. J Biol Chem 2006;281:12102-11.
29. Dieckgraefe BK, Weems DM. Epithelial injury induces egr-1 and fos expression by a pathway involving protein kinase C and ERK. Am J Physiol 1999;276:G322-30.
30. Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Le Tourneau C, Ogbourne SM, et al. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer 2008;99:1808-15.
31. Zhang H, Okamoto M, Panzhinskiy E, Zawada WM, Das M. PKCdelta/midkine pathway drives hypoxia-induced proliferation and differentiation of human lung epithelial cells. Am J Physiol Cell Physiol 2014;306:C648-58.
32. Papp H, Czifra G, Bodo E, Lazar J, Kovacs I, Aleksza M, et al. Opposite roles of protein kinase C isoforms in proliferation, differentiation, apoptosis, and tumorigenicity of human HaCaT keratinocytes. Cell Mol Life Sci 2004;61:1095-105.
33. Hernandez-Maqueda JG, Luna-Ulloa LB, Santoyo-Ramos P, Castaneda-Patlan MC, Robles-Flores M. Protein kinase C delta negatively modulates canonical Wnt pathway and cell proliferation in colon tumor cell lines. PLoS ONE 2013;8:e58540.
34. Bowles DK, Maddali KK, Dhulipala VC, Korzick DH. PKCdelta mediates anti-proliferative, pro-apoptic effects of testosterone on coronary smooth muscle. Am J Physiol Cell Physiol 2007;293:C805-13.
35. Serova M, Ghoul A, Benhadji KA, Faivre S, Le Tourneau C, Cvitkovic E, et al. Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. Mol Cancer Ther 2008;7:915-22.
36. Pritchard AL, Hayward NK. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. Clin Cancer Res 2013;19:2301-9.
37. Deschenes-Simard X, Gaumont-Leclerc MF, Bourdeau V, Lessard F, Moiseeva O, Forest V, et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev 2013;27:900-15.
38. Svensson S, Jirstrom K, Ryden L, Roos G, Emdin S, Ostrowski MC, et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005;24:4370-9.
39. Bernard J, Treton D, Vermot-Desroches C, Boden C, Horellou P, Angevin E, et al. Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13. Lab Invest 2001;81:1223-31.
40. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472-5.
41. Khoufache K, Bondza PK, Harir N, Daris M, Leboeuf M, Mailloux J, et al. Soluble human IL-1 receptor type 2 inhibits ectopic endometrial tissue implantation and growth: identification of a novel potential target for endometriosis treatment. Am J Pathol 2012;181:1197-205.